Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Rosacea treatments include topical creams and light therapy. The goal of treatment is to reduce inflammation. Find OTC and ...

Therapeutic systems contain multiple products that all work together to help reduce blemishes and heal your skin.

The right treatment for the right patient is key to ... among them comedones, papules, cysts, pustules, and abscesses which, after regression, may leave scars (see Figures 1-5).

Genetic mutations should be considered when selecting the optimal treatment for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to a recent network meta-analysis published in ...